DNA methylation analysis of secreted frizzled-related protein 2 gene for the early detection of colorectal cancer in fecal DNA

Babaei, Hadi; Mohammadi, Mohsen; Salehi, Roya

doi:10.4103/0300-1652.188357

Cited by 15 publications

(4 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Aberrant promoter methylation can result in silencing of gene expression and contribute to the development of leukemia. Changes in DNA methylation state (particularly hypermethylation of tumor suppressor genes) is a diagnostic and prognostic marker in patients with hematological malignancies [ 29 ]. Previous studies of the role of DNA methylation in AML have achieved conflicting results.…”

Section: Discussionmentioning

confidence: 99%

TET2 and MEG3 promoter methylation is associated with acute myeloid leukemia in a Hainan population

et al. 2017

View full text Add to dashboard Cite

The promoter of MEG3, which encodes the long non-coding RNA (lncRNA) MEG3, is often hypermethylated in acute myeloid leukemia (AML). Additionally, the Tet methylcytosine dioxygenase 2 gene (TET2) is frequently inactivated, which can lead to impaired DNA methylation and promote AML development. We examined the association between TET2 and MEG3 promoter hypermethylation in Hainan patients with AML. The expression of MEG3, TET2, miR-22-3p, and miR-22-5p was assessed in bone marrow samples from AML patients and healthy controls using real-time quantitative PCR. Using Sequenom MassARRAY technology, we compared MEG3 promoter methylation in AML patients and healthy controls. MEG3 expression was lower in AML patients than in the controls (P = 0.136). Moreover, there was greater methylation of MEG3 promoter in the AML patients than the controls (P < 0.05). Methylation of the MEG3 promoter correlated negatively with TET2 expression (P < 0.05, r < 0). Likewise there was a negative correlation between TET2 activity and MEG3 promoter methylation (P < 0.05, r < 0). These results suggest that hypermethylation of the MEG3 promoter in AML may result from decreased TET2 activity. These data provide insight into the molecular mechanisms underlying AML development and progression.

show abstract

Section: Discussionmentioning

confidence: 99%

TET2 and MEG3 promoter methylation is associated with acute myeloid leukemia in a Hainan population

et al. 2017

View full text Add to dashboard Cite

show abstract

“…SFRP2 hypermethylation was subsequently confirmed by other studies in stool samples from patients with CRC, adenomas, and advanced precancerous stages. Therefore, this marker would be a candidate in CRC screening tests [29][30][31][32][33][34][35][36].…”

Section: Genetic and Epigenetic Biomarkers From Stool For Crc Diagnosismentioning

confidence: 99%

Current Research on Molecular Biomarkers for Colorectal Cancer in Stool Samples

Órdenes,

Carril Pardo,

Elizondo-Vega

et al. 2023

Biology

View full text Add to dashboard Cite

Colorectal cancer (CRC) is one of the most diagnosed cancers worldwide, with a high incidence and mortality rate when diagnosed late. Currently, the methods used in healthcare to diagnose CRC are the fecal occult blood test, flexible sigmoidoscopy, and colonoscopy. However, the lack of sensitivity and specificity and low population adherence are driving the need to implement other technologies that can identify biomarkers that not only help with early CRC detection but allow for the selection of more personalized treatment options. In this regard, the implementation of omics technologies, which can screen large pools of biological molecules, coupled with molecular validation, stands out as a promising tool for the discovery of new biomarkers from biopsied tissues or body fluids. This review delves into the current state of the art in the identification of novel CRC biomarkers that can distinguish cancerous tissue, specifically from fecal samples, as this could be the least invasive approach.

show abstract

“…SFRP2 is one of the negative regulators of WNT signaling pathway. It has been observed that there were higher levels of SFRP2 hyper methylation in a sample of Iranian CRC patients compared with healthy subjects [ 58 ]. Similarly, there were also high levels of SFRP1 and SFRP2 hyper methylations among a group of Hungarian CRC patients [ 172 ].…”

Section: Signaling Pathwaysmentioning

confidence: 99%

“… Zare [ 57 ] SFRP2 2016 Colorectal 25 patients 25 controls Fecal Hyper methylation. Babaei [ 58 ] PTEN, miR-21 2016 Colorectal 125 N/T Tissue MiR-21 over expression, PTEN under expression. Yazdani [ 59 ] PTEN 2011 Breast 53 patients 20 controls Tissue Hyper methylation.…”

Section: Introductionmentioning

confidence: 99%

Methylation as a critical epigenetic process during tumor progressions among Iranian population: an overview

et al. 2021

View full text Add to dashboard Cite

Cancer is one of the main health challenges and leading causes of deaths in the world. Various environmental and genetic risk factors are associated with tumorigenesis. Epigenetic deregulations are also important risk factors during tumor progression which are reversible transcriptional alterations without any genomic changes. Various mechanisms are involved in epigenetic regulations such as DNA methylation, chromatin modifications, and noncoding RNAs. Cancer incidence and mortality have a growing trend during last decades among Iranian population which are significantly related to the late diagnosis. Therefore, it is required to prepare efficient molecular diagnostic panels for the early detection of cancer in this population. Promoter hyper methylation is frequently observed as an inhibitory molecular mechanism in various genes associated with DNA repair, cell cycle regulation, and apoptosis during tumor progression. Since aberrant promoter methylations have critical roles in early stages of neoplastic transformations, in present review we have summarized all of the aberrant methylations which have been reported during tumor progression among Iranian cancer patients. Aberrant promoter methylations are targetable and prepare novel therapeutic options for the personalized medicine in cancer patients. This review paves the way to introduce a non-invasive methylation specific panel of diagnostic markers for the early detection of cancer among Iranians.

show abstract

DNA methylation analysis of secreted frizzled-related protein 2 gene for the early detection of colorectal cancer in fecal DNA

Cited by 15 publications

References 22 publications

TET2 and MEG3 promoter methylation is associated with acute myeloid leukemia in a Hainan population

TET2 and MEG3 promoter methylation is associated with acute myeloid leukemia in a Hainan population

Current Research on Molecular Biomarkers for Colorectal Cancer in Stool Samples

Methylation as a critical epigenetic process during tumor progressions among Iranian population: an overview

Contact Info

Product

Resources

About